In human renal cancer cells, introduction of wild-type VHL specifically downregulated Cap43 among 9 tested genes that included thymosin beta‑4; thymosin beta‑4 was not named as downregulated.
In plain wordsIn kidney cancer cells, adding VHL lowered only Cap43 among 9 genes. The body's own thymosin beta‑4 gene was not named as lowered.
- Peptide
- Thymosin beta-4 (human)
- Outcome
- No significant changeThymosin beta-4 gene expression after VHL introduction
- Study
humann: not reported in source
VHL-negative 786-O renal cancer cells and VHL-positive 786/VHL-1 and 786/VHL-2 cells- Outcome group
- Receptor activity and mechanism · Cancer
Source sentences
Of these 9 genes, expression of the Cap43 gene was specifically downregulated by VHL.
2 context sentences(design, population, supporting numbers)
We previously identified 9 genes (i.e., thymosin beta4, secreted protein acidic and rich in cysteine, Cap43, ceruloplasmin, serum amyloid A, heat shock protein 90, LOT1, osteopontin and casein kinase Igamma) that are more highly expressed in cancerous regions than in noncancerous regions in human renal cancers.
We first established 2 VHL-positive cell lines, 786/VHL-1 and 786/VHL-2, after the introduction of wild-type VHL into VHL-negative renal cancer 786-O cells.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.